Amitkumar J Vyas,; Nensi D Santoki; Ajay I Patel; Ashvin V Dudhrejiya; Sunny R Shah; Devang B Sheth; Sandip P Dholakia
Abstract
Nowadays, use of antacids has drastically increased due to an increase in the intake of drugs with certain side effects, in which the dominant ‘acid release cycle’ is disturbed. ...
Read More
Nowadays, use of antacids has drastically increased due to an increase in the intake of drugs with certain side effects, in which the dominant ‘acid release cycle’ is disturbed. This resulted in the inclusion of Proton pump inhibitors in a major number of prescriptions. In individuals with gastroesophageal reflux disease and concurrent Helicobacter Pylori infection, proton pump inhibitors exhibit a significant limitation in providing relief from symptoms or adressing lingering issues associated with the sympathetic system, particularly during periods of rest such as sleep. Furthermore, this article summarises vonoprazan's effects on ‘triple drug therapy’. Through its inhibition of the stomach’s H+/K+ ATPase, Vonoprazan, a novel potassium-competitive acid blocker, has the potential to provide a reversible mechanism of action, leading to acid supression.It is anticipated that vonoprazan-based addiction therapy would be more effective for treatment for shorter period of time. In this study, the latest information provides a concise overview of the chemistry, biological properties, pharmacological, analytical methods, and clinical trials of Vonoprazan.
